Skip to content
ChickenStockChickenStock
ResearchIMNM
Immunome logo

Immunome (IMNM) stock

NASDAQ

$17.18-2.44%(-0.43)

As of the Nov 17, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-7.16x

Net loss — not comparable

P/B

4.46x

P/S

289.57x

Find stocks with P/B ≤ 0.9×

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Operating income decreased from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 9, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

18 SEC filings
  • Higgins JackChief Scientific Officer · Sep 11, 2026Open-market sale13,200 shares · $334K
    Avg. price $25.3265,050 shares held after
  • Higgins JackChief Scientific Officer · Sep 11, 2026Option exercise18,000 shares · $24K
    Avg. price $1.3578,250 shares held after
  • Higgins JackChief Scientific Officer · Sep 11, 2026Gift8,800 shares · $0
    Avg. price $056,250 shares held after
  • Barchas IsaacDirector · Aug 12, 2026Open-market sale11,048 shares · $301K
    Avg. price $27.2592,211 shares held after
  • Barchas IsaacDirector · Aug 11, 2026Open-market sale62,291 shares · $1.6M
    Avg. price $26.230 shares held after
  • Barchas IsaacDirector · Aug 10, 2026Open-market sale10,125 shares · $264K
    Avg. price $26.0762,291 shares held after
  • Barchas IsaacDirector · Aug 7, 2026Open-market sale15,248 shares · $397K
    Avg. price $26.0672,416 shares held after
  • Barchas IsaacDirector · Aug 6, 2026Open-market sale20,840 shares · $543K
    Avg. price $26.0687,664 shares held after
  • Horn KinneyCHIEF BUSINESS OFFICER · Aug 4, 2026Open-market sale90,616 shares · $2.3M
    Avg. price $25.090 shares held after
  • Horn KinneyCHIEF BUSINESS OFFICER · Aug 4, 2026Option exercise90,616 shares · $1.1M
    Avg. price $11.8895
    Show 2 price lots
    • 50,366 shares × $12.92$651K
    • 40,250 shares × $10.6$427K
  • Tsai PhilipChief Technical Officer · Jul 23, 2026Grant or award38,250 shares · $0
    Avg. price $081,550 shares held after
  • Lechleider RobertChief Medical Officer · Jul 23, 2026Grant or award54,000 shares · $0
    Avg. price $069,805 shares held after
  • Higgins JackChief Scientific Officer · Jul 23, 2026Grant or award38,250 shares · $0
    Avg. price $060,250 shares held after
  • Rosett MaxChief Financial Officer · Jul 23, 2026Grant or award47,250 shares · $0
    Avg. price $0101,287 shares held after
  • Horn KinneyCHIEF BUSINESS OFFICER · Jul 23, 2026Grant or award31,250 shares · $0
    Avg. price $031,250 shares held after
  • Stoneman Sandra G.CHIEF LEGAL OFFICER & GC · Jul 23, 2026Grant or award38,250 shares · $0
    Avg. price $043,805 shares held after
  • SIEGALL CLAY BPresident and CEO · Jul 23, 2026Grant or award180,000 shares · $0
    Avg. price $0870,704 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Immunome (IMNM) stock information

NASDAQ

Immunome (IMNM) is listed on NASDAQ. Its market capitalization is about $2B. On trailing-twelve-month earnings the P/E ratio is -7.16, and the P/B ratio is 4.46. Return on equity is -62.3%. These figures are computed in-house from official filings and are reference information only.

Immunome — frequently asked questions

What is the P/E ratio of Immunome (IMNM)?
On a trailing-twelve-month basis, IMNM trades at a P/E ratio of -7.16. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Immunome?
IMNM has a market capitalization of about $2B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.